MX2012013586A - Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante. - Google Patents
Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.Info
- Publication number
- MX2012013586A MX2012013586A MX2012013586A MX2012013586A MX2012013586A MX 2012013586 A MX2012013586 A MX 2012013586A MX 2012013586 A MX2012013586 A MX 2012013586A MX 2012013586 A MX2012013586 A MX 2012013586A MX 2012013586 A MX2012013586 A MX 2012013586A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- composition according
- modality
- cresol
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10164298 | 2010-05-28 | ||
| US35152210P | 2010-06-04 | 2010-06-04 | |
| PCT/EP2011/058648 WO2011147921A1 (en) | 2010-05-28 | 2011-05-26 | Stable multi-dose compositions comprising an antibody and a preservative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013586A true MX2012013586A (es) | 2013-01-24 |
Family
ID=42562357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013586A MX2012013586A (es) | 2010-05-28 | 2011-05-26 | Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130136733A1 (enExample) |
| EP (1) | EP2575761B1 (enExample) |
| JP (3) | JP6294075B2 (enExample) |
| KR (1) | KR20130086144A (enExample) |
| CN (2) | CN105055306B (enExample) |
| AU (1) | AU2011257219B2 (enExample) |
| BR (1) | BR112012030139A2 (enExample) |
| CA (1) | CA2800188A1 (enExample) |
| ES (1) | ES2993022T3 (enExample) |
| HR (1) | HRP20241526T1 (enExample) |
| MX (1) | MX2012013586A (enExample) |
| RS (1) | RS66182B1 (enExample) |
| RU (1) | RU2012153786A (enExample) |
| WO (1) | WO2011147921A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071096B2 (en) | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| KR20110039218A (ko) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | 항－인간 인터루킨－２０ 항체 |
| US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| PT2542257T (pt) | 2010-03-01 | 2017-10-09 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| WO2013123114A2 (en) * | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| EP3337827B1 (en) | 2015-08-19 | 2026-07-08 | Pfizer Inc. | Tissue factor pathway inhibitor antibodies and uses thereof |
| MA48763A (fr) * | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
| US20220008536A1 (en) * | 2018-11-16 | 2022-01-13 | Samsung Bioepis Co., Ltd. | Stable liquid composition comprising protein |
| MX2021015533A (es) | 2019-06-19 | 2022-02-10 | Silverback Therapeutics Inc | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. |
| AU2020385048A1 (en) * | 2019-11-13 | 2022-06-02 | Pfizer Inc. | Stable aqueous anti-TFPI antibody formulation |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| WO2022033981A1 (en) | 2020-08-12 | 2022-02-17 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| EP4216923A1 (en) * | 2020-09-24 | 2023-08-02 | Novo Nordisk Health Care AG | Pharmaceutical formulation of concizumab and method of production thereof |
| CN112244025A (zh) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用 |
| JPWO2024090488A1 (enExample) * | 2022-10-26 | 2024-05-02 | ||
| JP2026514305A (ja) * | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
| CN1270389C (zh) | 1996-06-28 | 2006-08-16 | 精工爱普生株式会社 | 薄膜晶体管及其制造方法 |
| DE69637856D1 (en) | 1996-08-30 | 2009-04-16 | Human Genome Sciences Inc | Interleukin-19. |
| US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| AU8571198A (en) | 1997-07-16 | 1999-02-10 | Human Genome Sciences, Inc. | Interleukin-20 |
| US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
| US6020163A (en) | 1997-08-06 | 2000-02-01 | Zymogenetics, Inc. | Lipocalin homolog |
| US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
| EP1047781B1 (en) | 1998-01-23 | 2004-07-28 | Immunex Corporation | Il-18 receptors |
| WO1999046379A2 (en) | 1998-03-09 | 1999-09-16 | Schering Corporation | Human receptor proteins; related reagents and methods |
| ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| WO1999062934A1 (en) | 1998-06-05 | 1999-12-09 | Human Genome Sciences, Inc. | Interferon receptor hkaef92 |
| US7071304B2 (en) | 1998-09-01 | 2006-07-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000015224A1 (en) | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
| US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
| AU2222700A (en) | 1998-12-31 | 2000-07-31 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
| JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| US20050060101A1 (en) | 1999-06-28 | 2005-03-17 | Bevilacqua Michael P. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| CZ305123B6 (cs) | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
| RU2279441C2 (ru) | 1999-12-23 | 2006-07-10 | Займодженетикс, Инк. | Выделенный растворимый il-20 рецептор (варианты) |
| US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| EP1272211B1 (en) | 2000-04-07 | 2007-06-06 | Signal Coordinating Therapy, Inc. | Methods and compositions for treating neoplasms |
| US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| AU2001276737A1 (en) | 2000-08-04 | 2002-02-18 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
| AU2001290524A1 (en) | 2000-08-08 | 2002-02-18 | Zymogenetics Inc. | Soluble zcytor 11 cytokine receptors |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US7101539B2 (en) | 2001-02-28 | 2006-09-05 | Eli Lilly And Company | Use of LP82 to treat hematopoietic disorders |
| JP4009535B2 (ja) | 2001-03-09 | 2007-11-14 | ザイモジェネティクス，インコーポレイティド | 可溶性ヘテロダイマーサイトカイン受容体 |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| EP3254687A1 (en) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
| US7022289B1 (en) | 2001-10-10 | 2006-04-04 | The United States Of America As Represented By The Secretary Of The Army | Chemical and biological sampling device and kit and method of use thereof |
| BRPI0214168B8 (pt) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| WO2003051384A1 (en) | 2001-12-17 | 2003-06-26 | Zymogenetics, Inc. | Method for treating cervical cancer |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| CA2476934C (en) | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| CA2481304A1 (en) | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20040009168A1 (en) * | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
| WO2005123131A2 (en) | 2004-06-14 | 2005-12-29 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
| MXPA04012116A (es) | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| AU2003251592A1 (en) | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| AU2003281528A1 (en) | 2002-07-18 | 2004-02-09 | Fabio Perini S.P.A. | Storage unit for elongated products |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| UA97086C2 (uk) | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
| CN100522998C (zh) | 2003-10-01 | 2009-08-05 | 协和发酵麒麟株式会社 | 抗体的稳定化方法和被稳定的溶液状抗体制剂 |
| WO2005063291A1 (ja) | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| EA015706B1 (ru) | 2004-10-22 | 2011-10-31 | Займоджинетикс, Инк. | Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела |
| WO2006086396A2 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
| US7525604B2 (en) | 2005-03-15 | 2009-04-28 | Naxellent, Llc | Windows with electrically controllable transmission and reflection |
| EP2264162A1 (en) | 2005-07-02 | 2010-12-22 | Arecor Limited | Stable aqueous systems comprising proteins |
| WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
| CA2618068C (en) | 2005-08-05 | 2016-02-16 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
| EP2161348A1 (en) | 2005-09-27 | 2010-03-10 | Source MDX | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| JP2009530699A (ja) | 2006-03-15 | 2009-08-27 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | ロール検出を備えたリモートコントロール型ポインティング技術 |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
| CA2647111A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
| EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
| JP2009540015A (ja) | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗ｅｇｆｒ抗体の凍結乾燥製剤 |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| CA2665567C (en) | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| KR20090069330A (ko) | 2006-10-12 | 2009-06-30 | 와이어쓰 | 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화 |
| US20100267575A1 (en) | 2006-10-17 | 2010-10-21 | Childrens Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| CA2668955A1 (en) | 2006-11-09 | 2008-05-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents |
| CN101553504A (zh) | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| WO2009077483A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| US20100273671A1 (en) | 2007-03-01 | 2010-10-28 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
| KR101087344B1 (ko) | 2007-03-23 | 2011-11-25 | 파나소닉 주식회사 | 도전성 범프와 그 제조 방법 및 전자 부품 실장 구조체 |
| KR101540823B1 (ko) | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| SG182183A1 (en) | 2007-06-08 | 2012-07-30 | Biogen Idec Inc | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| CA2690382A1 (en) | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| US20090004189A1 (en) | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| AU2008269086B2 (en) | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| US20100189721A1 (en) | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| EP2174132A2 (en) | 2007-07-20 | 2010-04-14 | National Institute for Bioprocessing Research and Training Limited | Glycosylation markers for cancer and chronic inflammation |
| US20100261613A1 (en) | 2007-07-26 | 2010-10-14 | Michael Centola | Methods for inflammatory disease management |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| CN103396480A (zh) | 2008-05-15 | 2013-11-20 | 诺沃—诺迪斯克有限公司 | 抗体纯化方法 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| KR20110039218A (ko) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | 항－인간 인터루킨－２０ 항체 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| KR20110048536A (ko) | 2008-08-28 | 2011-05-11 | 와이어쓰 엘엘씨 | 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도 |
| PE20110302A1 (es) | 2008-09-19 | 2011-05-21 | Hoffmann La Roche | Formulacion farmaceutica de un anticuerpo contra p-selectina |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| US20120020954A1 (en) | 2009-03-30 | 2012-01-26 | Anat Achiron | Methods of predicting clinical course and treating multiple sclerosis |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| US8580528B2 (en) | 2009-10-16 | 2013-11-12 | Stichting Vu-Vumc | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy |
| US20120208719A1 (en) | 2009-10-16 | 2012-08-16 | Mayo Foundation For Medical Education And Research | Assessing rheumatoid arthritis |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| WO2011154139A2 (en) | 2010-06-07 | 2011-12-15 | Roche Diagnostics Gmbh | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2011
- 2011-05-26 RU RU2012153786/10A patent/RU2012153786A/ru unknown
- 2011-05-26 CA CA2800188A patent/CA2800188A1/en not_active Withdrawn
- 2011-05-26 US US13/699,847 patent/US20130136733A1/en not_active Abandoned
- 2011-05-26 MX MX2012013586A patent/MX2012013586A/es unknown
- 2011-05-26 AU AU2011257219A patent/AU2011257219B2/en not_active Withdrawn - After Issue
- 2011-05-26 ES ES11721544T patent/ES2993022T3/es active Active
- 2011-05-26 JP JP2013511686A patent/JP6294075B2/ja active Active
- 2011-05-26 RS RS20241258A patent/RS66182B1/sr unknown
- 2011-05-26 HR HRP20241526TT patent/HRP20241526T1/hr unknown
- 2011-05-26 BR BR112012030139A patent/BR112012030139A2/pt not_active IP Right Cessation
- 2011-05-26 CN CN201510485529.1A patent/CN105055306B/zh active Active
- 2011-05-26 CN CN201180026538.4A patent/CN102905692B/zh active Active
- 2011-05-26 EP EP11721544.2A patent/EP2575761B1/en active Active
- 2011-05-26 KR KR1020127030515A patent/KR20130086144A/ko not_active Withdrawn
- 2011-05-26 WO PCT/EP2011/058648 patent/WO2011147921A1/en not_active Ceased
-
2016
- 2016-02-09 JP JP2016022657A patent/JP6239657B2/ja active Active
-
2017
- 2017-10-31 US US15/799,276 patent/US10835602B2/en active Active
- 2017-11-01 JP JP2017211614A patent/JP6568917B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011257219B2 (en) | 2014-12-04 |
| JP2016084367A (ja) | 2016-05-19 |
| RS66182B1 (sr) | 2024-12-31 |
| US20180104335A1 (en) | 2018-04-19 |
| WO2011147921A1 (en) | 2011-12-01 |
| EP2575761C0 (en) | 2024-08-14 |
| BR112012030139A2 (pt) | 2017-06-13 |
| US20130136733A1 (en) | 2013-05-30 |
| ES2993022T3 (en) | 2024-12-20 |
| CN105055306A (zh) | 2015-11-18 |
| HRP20241526T1 (hr) | 2025-01-03 |
| CN102905692A (zh) | 2013-01-30 |
| JP6239657B2 (ja) | 2017-11-29 |
| CN102905692B (zh) | 2015-09-16 |
| RU2012153786A (ru) | 2014-07-10 |
| AU2011257219A1 (en) | 2012-11-22 |
| CN105055306B (zh) | 2019-10-01 |
| EP2575761A1 (en) | 2013-04-10 |
| JP6294075B2 (ja) | 2018-03-14 |
| US10835602B2 (en) | 2020-11-17 |
| JP2013527189A (ja) | 2013-06-27 |
| CA2800188A1 (en) | 2011-12-01 |
| JP2018030879A (ja) | 2018-03-01 |
| KR20130086144A (ko) | 2013-07-31 |
| EP2575761B1 (en) | 2024-08-14 |
| JP6568917B2 (ja) | 2019-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10835602B2 (en) | Stable multi-dose compositions comprising an antibody and a preservative | |
| US10709782B2 (en) | Stable antibody containing compositions | |
| US20250367115A1 (en) | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | |
| US20160250329A1 (en) | Antibody composition | |
| US20170056504A1 (en) | Method of extending half-life of crystaline antibodies | |
| WO2016103034A1 (en) | Protein compositions and use thereof | |
| US20170267753A1 (en) | Combination therapy for co-administration of monoclonal antibodies | |
| TW202106711A (zh) | 抗體調配物 | |
| US20260091125A1 (en) | Multifunctional delivery system and uses thereof | |
| TW202045206A (zh) | 抗體調配物 |